RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $180 from $160 and keeps an Outperform rating on the shares. After a near best-case scenario for competitor Teva (TEVA) price discounting, the firm is adjusting its model accordingly to reflect better net pricing preservation for Ingrezza in the public channel in 2027-2028, as well as the out years, given likely less direct IRA impact, the analyst tells investors in a research note. The firm now expects more stable revenues, with sales peaking at $3.2B in 2030 vs. $3.0B in 2028 and a higher out-year tail, RBC added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $200 from $175 at TD Cowen
- Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
- Neurocrine Extends Eiry W. Roberts’ Employment Term
- Neurocrine’s Promising Prospects: Buy Rating Backed by Osavampator’s Success and Ingrezza’s Revenue Growth
- Neurocrine price target lowered to $173 from $178 at Morgan Stanley